ArticleTranslational cancer research2025
A novel fumaric acid metabolism-related prognostic signature associated with prognosis and immune infiltration landscape in laryngeal squamous cell carcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Laryngeal squamous cell carcinoma (LSCC) is an aggressive malignant tumor, characterized by high incidence and mortality. Metabolic pathways within cancer cells are frequently dysregulated; thus, exploring fumaric acid metabolism-related genes (FAMRGs) appears interesting. We aimed to identify a signature prognostic genetic profile to develop tailored management strategies for patients with LSCC. Methods: Data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and GeneCards databases were used to identify differentially expressed genes related to fumaric acid (FA) metabolism in LSCC. To explore the underlying mechanisms, we conducted analyses using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Additionally, we employed Cox regression and the least absolute shrinkage and selection operator (LASSO) to develop a risk signature based on FAMRGs. This signature was validated in TCGA and GEO cohorts. The association of the risk score with clinical characteristics, microenvironmental characteristics, and drug sensitivity was explored by correlation analyses. Finally, expression of FAMRGs was validated using datasets from the Gene Expression Profiling Interactive Analysis (GEPIA) and the Human Protein Atlas (HPA) databases. Moreover, the robustness of our findings was further confirmed through molecular docking and single-cell sequencing. Results: A FA metabolism-associated model for laryngeal cancer was constructed using seven genes ( Conclusions: A prognostic model associated with FA metabolism was established for LSCC based on seven genes. This model can effectively predict LSCC prognosis. Additionally, six small molecule drugs with potential therapeutic value for LSCC were identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.